Medical technology firm Becton, Dickinson and Company (BD) has secured approval from the US Food and Drug Administration (FDA) for its Totalys MultiProcessor and Totalys SlidePrep instruments.
The instruments, along with the BD FocalPoint SlideProfiler, form full Totalys system that further automates slide preparation, imaging and review for use in cervical cancer screening.
The system also includes the ancillary testing aliquot capability.
The BD DataLink middleware connects the Totalys instruments to a laboratory information system, allowing in providing continuous sample tracking to offer patients with the accurate results.
According to the company, the Totalys system combined with the SurePath liquid-based Pap test provides enhanced automated process for cervical cancer screening laboratories compared to current methods.
BD Women’s Health & Molecular Diagnostics general manager and vice president Doug White said: "The BD Totalys System provides clinical laboratories with a highly customizable, automated liquid-based cytology solution to help improve laboratory efficiency, enhance sample tracking and maintain high quality diagnostic results."
In February, BD received FDA 510(k) clearance and European CE marking for its new blood collection set.
The BD Vacutainer UltraTouch Push Button Blood Collection Set uses PentaPoint Comfort 5-bevel needle technology, which will provide access to difficult veins.